Parkside Financial Bank & Trust’s Apogee Therapeutics APGE Stock Holding History

Parkside Financial Bank & Trust’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.12K	Hold	31	–	–	﹤0.01%	1954
2026 Q1	$2.61K	Hold	31	–	–	﹤0.01%	2019
2025 Q4	$2.34K	Hold	31	–	–	﹤0.01%	2045
2025 Q3	$1.23K	Buy	31 +21	+210%	+$802	﹤0.01%	2201
2025 Q2	$435	Hold	10	–	–	﹤0.01%	2609
2025 Q1	$374	Buy	+10	New	+$387	﹤0.01%	2576

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Parkside Financial Bank & Trust's APGE Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 31 shares worth $4.12K. The position accounts for ﹤0.01% of the portfolio, ranked #1954.

Parkside Financial Bank & Trust first reported a position in APGE in Q1 2025 and has held it in 6 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Parkside Financial Bank & Trust held 31 shares of Apogee Therapeutics worth $4.12K as of Q2 2026.
Parkside Financial Bank & Trust left its Apogee Therapeutics share count unchanged in Q2 2026.
Apogee Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #1954 holding.
Parkside Financial Bank & Trust first reported a position in Apogee Therapeutics in Q1 2025 and has held it in 6 quarters since.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.